ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Up 35.0% in March

ADMA Biologics Inc (NASDAQ:ADMA) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 25,826,838 shares, a growth of 35.0% from the February 26th total of 19,137,458 shares. Currently, 11.3% of the company’s stock are sold short. Based on an average trading volume of 3,625,752 shares, the days-to-cover ratio is currently 7.1 days.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.00.

ADMA Biologics Stock Down 1.1%

Shares of ADMA Biologics stock opened at $9.15 on Tuesday. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $25.67. The company has a market capitalization of $2.18 billion, a PE ratio of 15.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The business has a 50-day moving average of $15.44 and a 200-day moving average of $16.37.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the previous year, the firm posted $0.46 earnings per share. The company’s revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts forecast that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares in the company, valued at $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently made changes to their positions in the business. Salomon & Ludwin LLC bought a new position in ADMA Biologics during the third quarter worth $25,000. Rothschild Investment LLC raised its holdings in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the period. Summit Securities Group LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth about $29,000. Clearstead Advisors LLC lifted its position in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $34,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.